Sidley represented ReCode Therapeutics in the fundraising. ReCode Therapeutics announced the closing of an extension to its Series B financing. The extension raised an additional $50...
You must be a Standard 1 Year member to access this content.
Sidley Austin represented ADARx Pharmaceuticals in the financing. ADARx Pharmaceuticals, Inc. announced its successful close of an oversubscribed $200 million Series C financing. The proceeds from...
You must be a Standard 1 Year member to access this content.
Zhong Lun advised Lepu Bio on the deal while Sidley represented Keymed Biosciences. Lepu Biopharma Co., Ltd and Keymed Biosciences Inc. signed a global exclusive license agreement...
You must be a Standard 1 Year member to access this content.
Sidley represented ADARx Pharmaceuticals, Inc. on the deal. ADARx Pharmaceuticals, Inc., a clinical-stage biotechnology company developing RNA-targeting therapeutics, announced its US$46 million Series B-1 financing. The proceeds...
You must be a Standard 1 Year member to access this content.
Freshfields Bruckhaus Deringer advised Indivumed GmbH on the deal while Sidley is represented Crown Bioscience. Indivumed GmbH sold its “IndivuServ” business unit to a wholly owned...
You must be a Standard 1 Year member to access this content.
Sidley advised Akeso Inc. on the deal. Akeso Inc. announced a high-profile US$5 billion collaboration and licensing agreement with Summit Therapeutics Inc. to out-license its breakthrough bispecific...
You must be a Standard 1 Year member to access this content.
Cooley LLP advised J.P. Morgan, Morgan Stanley, UBS and Evercore on the deal. Ropes & Gray and Wilmer Cutler Pickering Hale and Dorr LLP advised Altimeter,...
You must be a Standard 1 Year member to access this content.
